The minimal bactericidal concentrations of N-formimidoyl thienamycin (N-fthienamycin) against 21 strains of enterococci isolated from patients with infective endocarditis were determined by macro-and microdilution methods. By a macrodilution technique with the minimal bactericidal concentration defined as -99.9% killing of an initial inoculum, all 21 strains of enterococci were found to have minimal bactericidal concentration/minimal inhibitory concentration ratios of .32. The mean minimal inhibitory concentration was 1.5 ,g/ml (range, 0.5 to 4 ,Lg/ml), and the minimal bactericidal concentration was .128 ,ug/ml. The disparity between the results of our study and those published elsewhere, which reported that N-f-thienamycin is bactericidal in vitro against enterococci, may represent the relative insensitivity of the microdilution method in determining .99.9% killing. The lack of in vitro bactericidal activity of N-f-thienamycin against enterococci was confirmed in vivo in the rabbit model of experimental endocarditis. N-f-Thienamycin was no more effective than penicillin alone in the treatment of experimental enterococcal endocarditis and was less effective than the combination of penicillin and gentamicin. The results indicate that N-f-thienamycin should not be used alone in the treatment of enterococcal endocarditis.
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N-Formimidoyl thienamycin (N-f-thienamycin), a derivative of thienamycin, is a new betalactam antibiotic which is reported to be inhibitory (3, 5, 6, 8, 12, 14) and bactericidal (9) in vitro against enterococci. Since the successful treatment of enterococcal endocarditis necessitates the use of penicillin, ampicillin, or vancomycin in combination with an aminoglycoside, and since the aminoglycosides are associated with nephro-and ototoxicity, N-f-thienamycin might be useful as single-drug therapy for patients with endocarditis if it were bactericidal against enterococci in vitro and in vivo. The purpose of this study was to determine the bactericidal effect of N-f-thienamycin against enterococci by macro-and micro-broth dilution techniques and its efficacy in the treatment of experimental enterococcal endocarditis in animals. The wells in trays inoculated with 105 CFU/ml were subcultured after mixing on a microshaker, by methods described by Barry and Lasner (1), and the MBC was determined by the following methods: (i) 10 ,ul was streaked over the surface of a Mueller-Hinton agar plate; (ii) 1 ,ul was spot inoculated or streaked on the surface of a Mueller-Hinton plate.
MATERIALS AND METHODS
All subcultures were incubated at 35°C in air with 5% CO2 for 72 h. The MBC was defined as the lowest concentration of antibiotic that killed .99% or -99.9%o of the original inoculum (see below and Table  2 ).
Animal studies. (i) Rabbit model. Experimental aortic valve endocarditis was established in 57 New Zealand white rabbits (weight, .2 kg) by a modification of the method described by Garrison and Freedman (4) . A total of 78 rabbits were used during the study. Of these 57 were treated according to protocol. The remaining 21 animals (14 control and 7 treated with antimicrobial 'gents) died less than 3 days after the time of infection and could not be analyzed. Control animals were included throughout the course of the study. Animals were anesthetized with 60 mg of pentobarbital injected through a peripheral ear vein. An incision was n~ade in the neck, and the right carotid artery was exposed. The artery was ligated distally, and a sterile polyethylene catheter (radio-opaque Intramedic, PE 90; Clay-Adams, Parsipanny, N.J.) was inserted into the artery through a small incision and advanced proximally across the aortic valve into the left ventricle. A pressure-sensitive monitoring device was attached to the distal end of the catheter to ensure that the catheter tip crossed the aortic valve and entered the left ventricle. The catheter was left in place in the left ventricle for approximately 5 min and then withdrawn to a position just above the aortic valve. The distal end of the catheter was heat-sealed and tied to the carotid artery, and the wound was closed over the catheter with surgical clips. The catheter was left in place for 24 h before injection of bacteria.
(iH) Isolates. Two strains were selected from among the 18 strains of enterococci isolated from patients with endocarditis seen at the Mayo Clinic. The MIC and MBC of penicillin and N-f-thienamycin for the two strains of Streptococcus faecalis used were 1 pLg/ml and >128 p.g/ml, respectively. Of the 57 animals included in the study, 30 were infected with one strain and 27 were infected with the other. Enterococci were inoculated into Mueller-Hinton broth and incubated overnight. A (iii) Antibiotic assay. On day 2 of therapy, after the administration of the fourth dose of antibiotic, blood samples were obtained from a peripheral ear vein for measurement of serum concentration. Serum concentrations of penicillin were measured by bioassay (13) . Serum concentrations of gentamicin were measured by high-pressure liquid chromatography, and those of N-f-thienamycin were measured by a method described previously (7) .
(iv) Dose-response curves for N-f-thienamycin. Serum samples for assay were obtained by separate venipuncture at 5, 15, 30, 45, and 60 min and at 2, 3, and 4 h after i.m. injection of N-f-thienamycin at 20 mg/kg. No heparin was administered to any animals.
(v) SBT. Blood samples for determination of serum bactericidal titer (SBT) were obtained from a peripheral ear vein at 15 min after administration of N-fthienamycin and 1 h after administration of procaine penicillin or procaine penicillin plus gentamicin. Serum specimens were stored at -70°C. The SBT was measured by methods described elsewhere (13) .
Analysis of results. Differences in mean log1o CFU of enterococci per gram of vegetation were analyzed statistically by using the Kruskal-Wallis test and individual rank sum tests for differences between pairs (2, 11).
RESULTS
In vitro susceptibility of enterococci to aqueous penicillin G. The mean penicillin G MIC for the 21 strains of enterococci was 1.38 + 0.62 ,ug/ml; MBC was >128 ,ug/ml for all 21 strains. In vivo activity of N-f-thienamycin in animals.
The peak (mean, 17.6 ,ug/ml) serum concentration of N-f-thienamycin in seven rabbits occurred 15 min after administration of 20 mg/kg i.m. Four hours later, the mean serum concentration was <1 F&g/ml. In animals treated with 2 mg of gentamicin per kg i.m., the mean peak 1-h serum concentration was 8.8 Fg of gentamicin per ml. The mean concentration of procaine penicillin 1 h after administration of the dose was 17.6 ,ug/ml.
The results of treatment of experimental enterococcal endocarditis for 3 days with N-fthienamycin, procaine penicillin, and procaine penicillin plus gentamicin are shown in Table 3 . The efficacy of N-f-thienamycin was very similar to that of procaine penicillin alone and was less than that of procaine penicillin plus gentamicin (P < 0.001).
The peak SBT was <1:4 in animals treated with procaine penicillin, s1:2 in those treated with N-f-thienamycin, and :1:8 in those treated with penicillin plus gentamicin (Table 3) .
DISCUSSION
Our results agree with those of Eliopoulos and Moellering (3), who found that N-f-thienamycin was not bactericidal in vitro against enterococci, and in disagreement with those reported by Livingston et al. (9) , who reported that the MBC of N-f-thienamycin against enterococci was equal to or no more than twofold greater than the MIC. This disparity may represent the relative insensitivity of the microdilution method in detecting .99.9%o killing.
With an initial inoculum of 4.5 x 104 to 1 x 105 CFU/ml, subculture volume of 2 s.l, and an endpoint of c2 CFU, it is only possible to (10) .
The low SBT observed in animals treated with N-f-thienamycin is probably the result of defective killing of enterococci by this antibiotic, but may in part reflect the relative instability of N-fthienamycin in frozen serum specimens. The serum specimens from animals were frozen quickly to -70°C and thawed rapidly for SBT determination. The instability of N-f-thienamycin is minimized in serum that is frozen and thawed rapidly, and the influence on the results of SBTs in our study was probably negligible (H. Kropp, personal communication).
The lack of in vitro bactericidal activity of Nf-thienamycin against enterococci was confirmed in vivo in the rabbit model of experimental endocarditis. The clinical relevance of 99 versus 99.9o killing in bactericidal tests has been a matter of debate. The results of our studies with experimental endocarditis show that antimicrobial agents that kill .99%o of the inoculum are less effective than those which result in .99.9% killing. N-f-Thienamycin was no more effective than penicillin alone in the treatment of experimental enterococcal endocarditis and was less effective than the combination of penicillin and gentamicin. Therapeutic trials with N-f-thienamycin used alone in the treatment of human enterococcal endocarditis do not appear justified. In vitro synergy between N-f-thienamycin and gentamicin is similar to that observed with penicillin and gentamicin (3), but results of studies of experimental enterococcal endocarditis with N-f-thienamycin plus gentamicin have not been published.
